HIV, TB, inflammation and other correlates of serum phosphate: A cross-sectional study

Henrik Friis; N S Range; J Changalucha; George Amani PrayGod; K Jeremiah; Daniel Faurholt-Jepsen; H B Krarup; Andreas Bok Andersen; Pernille Kæstel; S Filteau

doi:10.1016/j.clnesp.2018.07.003

HIV, TB, inflammation and other correlates of serum phosphate: A cross-sectional study

Henrik Friis^*, N S Range, J Changalucha, George Amani PrayGod, K Jeremiah, Daniel Faurholt-Jepsen, H B Krarup, Andreas Bok Andersen, Pernille Kæstel, S Filteau

^*Corresponding author af dette arbejde

Ernæring og Sundhed hos børn og voksne

1 Citationer (Scopus)

Abstract

Background: There is little information about serum phosphate levels among patients with pulmonary tuberculosis (TB) and HIV infection.

Objective: We aimed to assess the role of TB, HIV, inflammation and other correlates on serum phosphate levels.

Methods: A cross-sectional study was conducted among TB patients and age- and sex-matched non-TB controls. Pulmonary TB patients were categorized as sputum -negative and -positive, based on culture. Age- and sex-matched non-TB controls were randomly selected among neighbours to sputum-positive TB patients. Data on age, sex, alcohol and smoking habits were obtained. HIV status, serum phosphate, and the acute phase reactants C-reactive protein (serum CRP) and α₁-acid glycoprotein (serum AGP) were determined. Linear regression analysis was used to identify correlates of serum phosphate.

Results: Of 1605 participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients, of which 9.9% and 50.4% were HIV-infected. Serum phosphate was determined before start of TB treatment in 44%, and 1–14 days after start of treatment in 56%. Serum phosphate was up to 0.10 mmol/L higher 1–3 days after start of TB treatment, and lowest 4 days after treatment, after which it increased. In multivariable analysis, TB patients had 0.09 (95% CI: 0.05; 0.13) mmol/L higher serum phosphate than controls, and those with HIV had 0.05 (95% CI: 0.01; 0.08) mmol/L higher levels than those without. Smoking was also a positive correlate of serum phosphate, whereas male sex and age were negative correlates.

Conclusion: While HIV and TB are associated with higher serum phosphate, our data suggest that TB treatment is followed by transient reductions in serum phosphate, which may reflect hypophosphataemia in some patients.

Originalsprog	Engelsk
Tidsskrift	Clinical Nutrition ESPEN
Vol/bind	27
Sider (fra-til)	38-43
Antal sider	6
ISSN	2405-4577
DOI	https://doi.org/10.1016/j.clnesp.2018.07.003
Status	Udgivet - okt. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.clnesp.2018.07.003

Citationsformater

@article{2307b03a28d04160989d855acc65962a,

title = "HIV, TB, inflammation and other correlates of serum phosphate: A cross-sectional study",

abstract = "Background: There is little information about serum phosphate levels among patients with pulmonary tuberculosis (TB) and HIV infection. Objective: We aimed to assess the role of TB, HIV, inflammation and other correlates on serum phosphate levels. Methods: A cross-sectional study was conducted among TB patients and age- and sex-matched non-TB controls. Pulmonary TB patients were categorized as sputum -negative and -positive, based on culture. Age- and sex-matched non-TB controls were randomly selected among neighbours to sputum-positive TB patients. Data on age, sex, alcohol and smoking habits were obtained. HIV status, serum phosphate, and the acute phase reactants C-reactive protein (serum CRP) and α1-acid glycoprotein (serum AGP) were determined. Linear regression analysis was used to identify correlates of serum phosphate. Results: Of 1605 participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients, of which 9.9% and 50.4% were HIV-infected. Serum phosphate was determined before start of TB treatment in 44%, and 1–14 days after start of treatment in 56%. Serum phosphate was up to 0.10 mmol/L higher 1–3 days after start of TB treatment, and lowest 4 days after treatment, after which it increased. In multivariable analysis, TB patients had 0.09 (95% CI: 0.05; 0.13) mmol/L higher serum phosphate than controls, and those with HIV had 0.05 (95% CI: 0.01; 0.08) mmol/L higher levels than those without. Smoking was also a positive correlate of serum phosphate, whereas male sex and age were negative correlates. Conclusion: While HIV and TB are associated with higher serum phosphate, our data suggest that TB treatment is followed by transient reductions in serum phosphate, which may reflect hypophosphataemia in some patients.",

keywords = "Acute phase response, HIV, Phosphorus, Serum phosphate, Tuberculosis",

author = "Henrik Friis and Range, {N S} and J Changalucha and PrayGod, {George Amani} and K Jeremiah and Daniel Faurholt-Jepsen and Krarup, {H B} and Andersen, {Andreas Bok} and Pernille K{\ae}stel and S Filteau",

note = "CURIS 2018 NEXS 265",

year = "2018",

month = oct,

doi = "10.1016/j.clnesp.2018.07.003",

language = "English",

volume = "27",

pages = "38--43",

journal = "Clinical Nutrition ESPEN",

issn = "2405-4577",

publisher = "Elsevier",

}

TY - JOUR

T1 - HIV, TB, inflammation and other correlates of serum phosphate

T2 - A cross-sectional study

AU - Friis, Henrik

AU - Range, N S

AU - Changalucha, J

AU - PrayGod, George Amani

AU - Jeremiah, K

AU - Faurholt-Jepsen, Daniel

AU - Krarup, H B

AU - Andersen, Andreas Bok

AU - Kæstel, Pernille

AU - Filteau, S

N1 - CURIS 2018 NEXS 265

PY - 2018/10

Y1 - 2018/10

N2 - Background: There is little information about serum phosphate levels among patients with pulmonary tuberculosis (TB) and HIV infection. Objective: We aimed to assess the role of TB, HIV, inflammation and other correlates on serum phosphate levels. Methods: A cross-sectional study was conducted among TB patients and age- and sex-matched non-TB controls. Pulmonary TB patients were categorized as sputum -negative and -positive, based on culture. Age- and sex-matched non-TB controls were randomly selected among neighbours to sputum-positive TB patients. Data on age, sex, alcohol and smoking habits were obtained. HIV status, serum phosphate, and the acute phase reactants C-reactive protein (serum CRP) and α1-acid glycoprotein (serum AGP) were determined. Linear regression analysis was used to identify correlates of serum phosphate. Results: Of 1605 participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients, of which 9.9% and 50.4% were HIV-infected. Serum phosphate was determined before start of TB treatment in 44%, and 1–14 days after start of treatment in 56%. Serum phosphate was up to 0.10 mmol/L higher 1–3 days after start of TB treatment, and lowest 4 days after treatment, after which it increased. In multivariable analysis, TB patients had 0.09 (95% CI: 0.05; 0.13) mmol/L higher serum phosphate than controls, and those with HIV had 0.05 (95% CI: 0.01; 0.08) mmol/L higher levels than those without. Smoking was also a positive correlate of serum phosphate, whereas male sex and age were negative correlates. Conclusion: While HIV and TB are associated with higher serum phosphate, our data suggest that TB treatment is followed by transient reductions in serum phosphate, which may reflect hypophosphataemia in some patients.

AB - Background: There is little information about serum phosphate levels among patients with pulmonary tuberculosis (TB) and HIV infection. Objective: We aimed to assess the role of TB, HIV, inflammation and other correlates on serum phosphate levels. Methods: A cross-sectional study was conducted among TB patients and age- and sex-matched non-TB controls. Pulmonary TB patients were categorized as sputum -negative and -positive, based on culture. Age- and sex-matched non-TB controls were randomly selected among neighbours to sputum-positive TB patients. Data on age, sex, alcohol and smoking habits were obtained. HIV status, serum phosphate, and the acute phase reactants C-reactive protein (serum CRP) and α1-acid glycoprotein (serum AGP) were determined. Linear regression analysis was used to identify correlates of serum phosphate. Results: Of 1605 participants, 355 (22.1%) were controls and 1250 (77.9%) TB patients, of which 9.9% and 50.4% were HIV-infected. Serum phosphate was determined before start of TB treatment in 44%, and 1–14 days after start of treatment in 56%. Serum phosphate was up to 0.10 mmol/L higher 1–3 days after start of TB treatment, and lowest 4 days after treatment, after which it increased. In multivariable analysis, TB patients had 0.09 (95% CI: 0.05; 0.13) mmol/L higher serum phosphate than controls, and those with HIV had 0.05 (95% CI: 0.01; 0.08) mmol/L higher levels than those without. Smoking was also a positive correlate of serum phosphate, whereas male sex and age were negative correlates. Conclusion: While HIV and TB are associated with higher serum phosphate, our data suggest that TB treatment is followed by transient reductions in serum phosphate, which may reflect hypophosphataemia in some patients.

KW - Acute phase response

KW - HIV

KW - Phosphorus

KW - Serum phosphate

KW - Tuberculosis

U2 - 10.1016/j.clnesp.2018.07.003

DO - 10.1016/j.clnesp.2018.07.003

M3 - Journal article

C2 - 30144891

AN - SCOPUS:85051113596

SN - 2405-4577

VL - 27

SP - 38

EP - 43

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

ER -

HIV, TB, inflammation and other correlates of serum phosphate: A cross-sectional study

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater